

Please amend the claims as follows:

Claims 1-19 (Canceled)

Newly presented claims are as follows:

20. (NEW) A high melting polymorphic form of (+)-(S)-clopidogrel bisulfate Form-I.
21. (NEW) The Form-I of clopidogrel bisulfate of claim 20, wherein the clopidogrel has a melting point of 198°C to 200 °C.
22. (NEW) The Form-I of clopidogrel bisulfate of claim 20, wherein the clopidogrel has a purity of more than 99% by HPLC.
23. (NEW) The Form-I of clopidogrel bisulfate of claim 22, wherein the clopidogrel has a purity of more than 99.96%.
24. (NEW) The Form-I of clopidogrel bisulfate of claim 20, wherein the clopidogrel has a particle size (d 0.9) of from about 62 to about 426 microns.
25. (NEW) Pure (+)-(S)-clopidogrel bisulfate Form-I having a purity of more than 99 %.
26. (NEW) The pure (+)-(S)-clopidogrel bisulfate Form-I of claim 25, wherein the clopidogrel has a purity of more than 99.96 %.
27. (NEW) The pure (+)-(S)-clopidogrel bisulfate Form-I of claim 25, wherein the clopidogrel has a melting point 198 to 200 °C.
28. (NEW) The pure (+)-(S)-clopidogrel bisulfate Form-I of claim 25, wherein the clopidogrel has a particle size (d 0.9) from about 62 to about 426 microns.
29. (NEW) A pharmaceutical composition comprising a high melting polymorphic form of (+)-(S)-clopidogrel bisulfate Form-I.

30. (NEW) A pharmaceutical composition comprising the pure (+)-(S)-clopidogrel bisulfate Form-I of claim 25.
31. (NEW) A process for the preparation of (+)-(S)-clopidogrel bisulfate Form-I, the process comprising:
- a) dissolving (+)-(S)-clopidogrel in an ester solvent;
  - b) adding sulfuric acid; and
  - c) isolating (+)-(S)-clopidogrel bisulfate Form-I.
32. (NEW) The process of claim 31 further comprising drying of the product obtained.
33. (NEW) The process of claim 31, wherein the solvent is ethyl acetate.
34. (NEW) The process of claim 31, wherein the Form-I of clopidogrel bisulfate has a melting point of 198°C to 200 °C.
35. (NEW) The process of claim 31, wherein the Form-I of clopidogrel bisulfate has a purity of more than 99% by HPLC.
36. (NEW) The process of claim 31, wherein the Form-I of clopidogrel bisulfate has a purity of more than 99.96% by HPLC.
37. (NEW) The process of claim 31, wherein the Form-I of clopidogrel bisulfate has a particle size (d 0.9) from about 62 to about 426 microns.
38. (NEW) A process for the preparation of pure (+)-(S)-clopidogrel bisulfate Form-I having a purity of more than 99 %, the process comprising:
- a) dissolving (+)-(S)-clopidogrel in an ester solvent;
  - b) adding sulfuric acid; and
  - c) isolating the pure (+)-(S)-clopidogrel bisulfate Form-I having a purity of more than 99%.
39. (NEW) The process of claim 38, wherein the solvent is ethyl acetate.
40. (NEW) The process of claim 38, wherein the Form-I of clopidogrel bisulfate has a melting point of 198°C to 200 °C.